Open access
Open access
Powered by Google Translator Translator

Pediatrics – Hematology

Preliminary study suggests that Edoxaban is a safe alternative for preventing thromboembolism in pediatric patients with cardiac disease.

9 Dec, 2022 | 13:07h | UTC

Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Advancing Anticoagulation for Children With Cardiac Disease – Journal of the American College of Cardiology

Commentary: Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease – ENNOBLE-ATE – American College of Cardiology

Related: [Abstract Only] Randomized Trial: Direct Oral Anticoagulant Similarly Effective as Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children

 


RCT | Leniolisib for Activated phosphoinositide 3-kinase delta syndrome.

22 Nov, 2022 | 13:12h | UTC

Randomized, Placebo-Controlled, Phase 3 Trial of PI3Kδ Inhibitor Leniolisib for Activated PI3Kδ Syndrome – Blood 

 


Review | Thrombotic microangiopathy in children.

5 Aug, 2022 | 13:56h | UTC

Thrombotic microangiopathy in children – Pediatric Nephrology (if the link is paywalled, try this one)

 


Cohort Study | Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine.

3 Aug, 2022 | 13:53h | UTC

Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate Vaccine in France – JAMA Network Open

 

Commentary on Twitter

 


Guideline | Role of IVIG in the management of Rh- and ABO-mediated hemolytic disease of the newborn.

2 Aug, 2022 | 12:18h | UTC

International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn – British Journal of Haematology

 


RCT | Ticagrelor is ineffective for reducing vaso-occlusive crises in pediatric sickle cell disease.

25 Jul, 2022 | 12:50h | UTC

Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study – Blood

 


Review | Sickle cell disease.

7 Jul, 2022 | 12:59h | UTC

Sickle Cell Disease: A Review – JAMA (free for a limited period)

Audio Clinical Review: Sickle Cell Disease – JAMA

 


Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.

24 Jun, 2022 | 11:13h | UTC

Egyptian evidence-based consensus on clinical practice guidelines for the diagnosis and treat-to-target management of macrophage activation syndrome in children – Egyptian Rheumatology and Rehabilitation

 


Stay Updated in Your Specialty

No spam, just news.